TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors - TC-210 induced tumor regression in all of the first eight patients - Ovarian cancer patient achieved confirmed RECIST partial response (PR) - Overall response rate (ORR) 50% in patients...

TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...

TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity - ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...

TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors - TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients - Two RECIST unconfirmed partial responses and two patients with stable disease through six months       - Manageable...